To investigate the role of serum pepsinogen i, pepsinogen II and TFF3 in predicting the risk of gastric cancer development.

Ended Purchase Order Awarded

Contract number
75N91020P00900
Awardee
Awarding agency
Obligated
$84,990

Award facts

Opportunity
Contract value 100% obligated
$84,990.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541990 All Other Professional, Scientific, and Technical Services
PSC
B529 Special Studies/Analysis- Scientific Data
Set-aside
No set-aside
Competition
Not Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Latvia

Award details come from SAM.gov/FPDS.

About this award

The National Cancer Institute awarded a purchase order to Labmedtech AS for $84,990 on September 15, 2020, to investigate the role of serum pepsinogen I, pepsinogen II, and TFF3 in predicting gastric cancer development risk. Work is performed in Latvia under firm fixed price terms. The order was solicited as a pre-solicitation opportunity posted April 22, 2020, with a due date of April 30, 2020. Performance concludes September 14, 2021.

Quick answers

Who was awarded contract 75N91020P00900?

75N91020P00900 was awarded to Labmedtech AS by National Cancer Institute (National Institutes of Health) on September 15, 2020.

How much is contract 75N91020P00900 worth?

The government has obligated $84,990 on 75N91020P00900.

Was contract 75N91020P00900 competed?

The extent of competition for 75N91020P00900 was not competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award